Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Strong Sell Rating by Wall Street Zen

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "strong sell" rating in a research note issued on Saturday.

• 2 low-priced gene therapy stocks to speculate on

A number of other research firms have also recently commented on SGMO. Barclays reaffirmed an "equal weight" rating and set a $1.00 price target (down from $5.00) on shares of Sangamo Therapeutics in a research note on Friday, November 7th. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, September 4th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Sangamo Therapeutics in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $3.83.

Check Out Our Latest Research Report on SGMO

Sangamo Therapeutics Stock Performance

NASDAQ SGMO opened at $0.44 on Friday. The business's 50 day moving average price is $0.59 and its 200-day moving average price is $0.56. Sangamo Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $2.84. The company has a market cap of $149.64 million, a P/E ratio of -1.53 and a beta of 1.25.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.08). Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%.The firm had revenue of $0.58 million for the quarter, compared to analysts' expectations of $34.40 million. As a group, equities analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several large investors have recently modified their holdings of SGMO. Golden State Equity Partners lifted its position in shares of Sangamo Therapeutics by 5.4% in the 2nd quarter. Golden State Equity Partners now owns 391,943 shares of the biopharmaceutical company's stock worth $212,000 after purchasing an additional 20,000 shares during the period. World Investment Advisors raised its stake in Sangamo Therapeutics by 88.5% in the third quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 20,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Sangamo Therapeutics by 30.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 90,550 shares of the biopharmaceutical company's stock worth $48,000 after buying an additional 21,300 shares during the period. Wealth Management Associates Inc. boosted its position in Sangamo Therapeutics by 9.1% during the 3rd quarter. Wealth Management Associates Inc. now owns 335,800 shares of the biopharmaceutical company's stock valued at $226,000 after acquiring an additional 28,000 shares in the last quarter. Finally, Meritage Portfolio Management increased its holdings in shares of Sangamo Therapeutics by 37.3% in the 2nd quarter. Meritage Portfolio Management now owns 127,000 shares of the biopharmaceutical company's stock valued at $69,000 after acquiring an additional 34,500 shares during the period. Institutional investors own 56.92% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Further Reading

• Five stocks we like better than Sangamo Therapeutics
• Unveiling The Power Of VWAP: A Key Indicator For Traders
• Are These 3 Oversold Tech Giants Ready to Rebound?
• Health Care Stocks Explained: Why You Might Want to Invest
• If You Wait for the Dip, Micron Technology Could Leave You Behind
• Top Biotech Stocks: Exploring Innovation Opportunities
• 3 Stocks Quietly Powering the AI and Tech Revolution

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sangamo Therapeutics Right Now?

Before you consider Sangamo Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sangamo Therapeutics wasn't on the list.

While Sangamo Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here